FDA clears Edesa Biotech IND for Phase 2 vitiligo drug study
Tweet Send to a Friend
Edesa Biotech, Inc. (Nasdaq: EDSA) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




